Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist prescribed for type 2 diabetes and chronic weight management
However, for long-term effects of the GLP-1-based therapies, more trials data will be required
UHC classifies Zepbound as a specialty-tier medication, which means higher cost-sharing and strict prior authorization (PA) requirements apply
(2015) found that active GLP-1 levels in diabetic mice transplanted with islet grafts were significantly increased following treatment with EX-4 compared to untreated control
US$ 21.84
US$ 23.20
US$ 21.22
US$ 27.62
US$ 28.75
